Concepts (84)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Disease, Chronic Obstructive | 2 | 2024 | 62 | 1.390 |
Why?
|
| Students, Pharmacy | 2 | 2025 | 83 | 1.020 |
Why?
|
| Common Cold | 1 | 2025 | 2 | 0.970 |
Why?
|
| Nonprescription Drugs | 1 | 2025 | 8 | 0.970 |
Why?
|
| Nasal Decongestants | 1 | 2025 | 3 | 0.970 |
Why?
|
| Pharmacists | 2 | 2024 | 73 | 0.970 |
Why?
|
| Phenylephrine | 1 | 2025 | 14 | 0.970 |
Why?
|
| Nasal Obstruction | 1 | 2025 | 7 | 0.970 |
Why?
|
| Cannabinoids | 1 | 2024 | 9 | 0.920 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2025 | 41 | 0.910 |
Why?
|
| Methocarbamol | 1 | 2024 | 1 | 0.900 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2024 | 41 | 0.890 |
Why?
|
| Polyethylene Glycols | 1 | 2024 | 100 | 0.830 |
Why?
|
| Asthma | 1 | 2024 | 60 | 0.820 |
Why?
|
| Rhabdomyolysis | 1 | 2022 | 6 | 0.770 |
Why?
|
| Muscular Diseases | 1 | 2022 | 12 | 0.770 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2022 | 75 | 0.740 |
Why?
|
| Dermal Fillers | 1 | 2021 | 1 | 0.720 |
Why?
|
| Ocular Hypertension | 1 | 2020 | 11 | 0.710 |
Why?
|
| Patient Transfer | 2 | 2018 | 43 | 0.700 |
Why?
|
| Glaucoma, Open-Angle | 1 | 2020 | 23 | 0.690 |
Why?
|
| Pulmonary Embolism | 1 | 2021 | 126 | 0.650 |
Why?
|
| Megestrol Acetate | 1 | 2019 | 5 | 0.650 |
Why?
|
| Rivaroxaban | 1 | 2019 | 29 | 0.630 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2019 | 46 | 0.620 |
Why?
|
| Pharmacy Residencies | 1 | 2018 | 6 | 0.580 |
Why?
|
| Accreditation | 1 | 2018 | 36 | 0.580 |
Why?
|
| Education, Pharmacy, Graduate | 1 | 2018 | 18 | 0.570 |
Why?
|
| Self Care | 1 | 2018 | 42 | 0.570 |
Why?
|
| Humans | 13 | 2025 | 28121 | 0.540 |
Why?
|
| Heart Failure | 1 | 2018 | 247 | 0.470 |
Why?
|
| Aftercare | 2 | 2024 | 33 | 0.400 |
Why?
|
| Patient Discharge | 2 | 2024 | 103 | 0.380 |
Why?
|
| United States | 2 | 2025 | 2149 | 0.250 |
Why?
|
| United States Food and Drug Administration | 1 | 2025 | 45 | 0.240 |
Why?
|
| Administration, Oral | 1 | 2025 | 189 | 0.230 |
Why?
|
| Excipients | 1 | 2024 | 4 | 0.220 |
Why?
|
| Acidosis | 1 | 2024 | 11 | 0.220 |
Why?
|
| Administration, Intravenous | 1 | 2024 | 30 | 0.220 |
Why?
|
| Social Workers | 1 | 2024 | 5 | 0.220 |
Why?
|
| Educational Measurement | 1 | 2025 | 128 | 0.220 |
Why?
|
| Bronchodilator Agents | 1 | 2024 | 15 | 0.220 |
Why?
|
| Patients | 1 | 2024 | 17 | 0.220 |
Why?
|
| Kidney Diseases | 1 | 2024 | 59 | 0.220 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2024 | 75 | 0.210 |
Why?
|
| Interprofessional Relations | 1 | 2024 | 66 | 0.210 |
Why?
|
| Mental Health | 1 | 2024 | 99 | 0.210 |
Why?
|
| Education, Pharmacy | 1 | 2025 | 116 | 0.200 |
Why?
|
| Drug Overdose | 1 | 2022 | 11 | 0.200 |
Why?
|
| Curriculum | 1 | 2025 | 291 | 0.200 |
Why?
|
| Colchicine | 1 | 2022 | 16 | 0.190 |
Why?
|
| Drug Interactions | 1 | 2022 | 78 | 0.190 |
Why?
|
| Oklahoma | 1 | 2025 | 1005 | 0.180 |
Why?
|
| Medication Therapy Management | 1 | 2021 | 18 | 0.180 |
Why?
|
| Ophthalmic Solutions | 1 | 2020 | 27 | 0.180 |
Why?
|
| beta-Alanine | 1 | 2020 | 12 | 0.180 |
Why?
|
| Benzoates | 1 | 2020 | 30 | 0.170 |
Why?
|
| Intraocular Pressure | 1 | 2020 | 62 | 0.170 |
Why?
|
| Antihypertensive Agents | 1 | 2020 | 56 | 0.170 |
Why?
|
| Cross-Sectional Studies | 1 | 2024 | 968 | 0.170 |
Why?
|
| Case-Control Studies | 1 | 2022 | 722 | 0.160 |
Why?
|
| Polymers | 1 | 2021 | 117 | 0.160 |
Why?
|
| Dabigatran | 1 | 2019 | 20 | 0.160 |
Why?
|
| Florida | 1 | 2019 | 54 | 0.160 |
Why?
|
| Child | 1 | 2025 | 2242 | 0.150 |
Why?
|
| Retrospective Studies | 2 | 2022 | 2557 | 0.150 |
Why?
|
| Accountable Care Organizations | 1 | 2018 | 3 | 0.150 |
Why?
|
| Treatment Outcome | 1 | 2024 | 2380 | 0.150 |
Why?
|
| Outpatients | 1 | 2018 | 44 | 0.140 |
Why?
|
| Self-Management | 1 | 2018 | 13 | 0.140 |
Why?
|
| Professional Role | 1 | 2018 | 46 | 0.140 |
Why?
|
| Patient Care Team | 1 | 2018 | 66 | 0.140 |
Why?
|
| Pharmaceutical Services | 1 | 2018 | 41 | 0.140 |
Why?
|
| Patient Readmission | 1 | 2018 | 103 | 0.130 |
Why?
|
| Primary Health Care | 1 | 2018 | 152 | 0.130 |
Why?
|
| Disease Progression | 1 | 2018 | 473 | 0.130 |
Why?
|
| Adult | 1 | 2021 | 7757 | 0.080 |
Why?
|
| Female | 2 | 2022 | 15156 | 0.070 |
Why?
|
| Male | 1 | 2019 | 13487 | 0.050 |
Why?
|
| Naloxone | 1 | 2022 | 19 | 0.050 |
Why?
|
| Analgesics, Opioid | 1 | 2022 | 113 | 0.050 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2022 | 163 | 0.050 |
Why?
|
| Cohort Studies | 1 | 2022 | 886 | 0.040 |
Why?
|
| Aged | 1 | 2022 | 5416 | 0.030 |
Why?
|